TheraVectys SA.

Showcase Sponsor

TheraVectys, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift to vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health and may well be the biggest silent revolution in immunotherapies.